communal bathing facilities. Onychomycosis is a fungal infection of the fingernails and toenails that accounts for about 30% of … (e.g. pulse therapy). Also, newer drugs for onychomycosis have improved tolerability profiles compared with older agents …. The overall costs of treating onychomycosis are substantial, and it has been estimated that direct cost for US Medicare …

Itraconazole in Onychomycosis (L.I.ON.) study, a randomised controlled trial comparing continuous terbinafine with intermittent … itraconazole. The trial included 4 treatment arms: terbinafine 250 mg/day for 12 or 16 weeks (T12, T16) and itraconazole 400 mg … itraconazole in the treatment of dermatophyte toenail onychomycosis. …

Objective: To determine the cost effectiveness of terbinafine (Lamisil(R)) tablets compared with fluconazole (Diflucan … fluconazole 150mg once weekly for 12 weeks (n = 45) or 24 weeks (n = 44) in patients with culture-confirmed toenail onychomycosis … of terbinafine for each complete clinical cure was superior to that of either of the fluconazole regimens. Costs per cure …

recognised. Included in this list are the azole antifungal drugs, ketoconazole, fluconazole and itraconazole; the calcium channel …

assess the cost effectiveness of itraconazole compared with both fluconazole and no prophylaxis for the prevention of … fluconazole and itraconazole and no prophylaxis. The perspective of the analysis was that of the healthcare sector; only medical …-saving to _5000 per invasive fungal infection averted). Compared with fluconazole, itraconazole is estimated to be both more …

effectiveness between oral antifungal medication and local therapy for patients with toenail onychomycosis. Design: Prospective …, observational study of patients with onychomycosis who visited dermatologists and podiatrists in the US. Physicians provided data on … of follow-up in patients with toenail onychomycosis, the use of oral antifungal medication resulted in superior patient …

Fluconazole (FLU) is an alternative to amphotericin B (AMB) for the treatment of candidemia in non-neutropenic patients …

patients, particularly those in the ICU. Both fluconazole and the echinocandins are recommended as first-line therapy for C … intravenously daily) versus those of fluconazole (800 mg intravenously on day 1, then 400 mg intravenously daily) as first … fluconazole for C/IC were reviewed. Patients who were in the ICU at study entry were identified, and the following data, collected …

The symptoms of onychomycosis and their impact on personal appearance are important determinants of patients …' perceptions of their own health. The effect of onychomycosis is greater on psychosocial than physical functioning and is directly … developed to assess the impact of onychomycosis and its treatment on health-related quality of life (HR-QOL). The instruments …